AbbVie (NYSE: ABBV) reported Q4 EPS of $1.90, $0.03 worse than the analyst estimate of $1.93. Revenue for the quarter came in at $8.31 billion versus the consensus estimate of $8.36 billion.

GUIDANCE:

AbbVie sees FY2019 EPS of $8.65-$8.75, versus the consensus of $8.71.

• AbbVie is issuing GAAP diluted EPS guidance for the full-year 2019 of $7.39 to $7.49. The company's 2019 GAAP guidance does not reflect non-cash charges for contingent consideration adjustments related to the expected approval of risankizumab in the first half of the year. AbbVie expects to deliver adjusted diluted EPS for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point. The company's 2019 adjusted diluted EPS guidance excludes $1.26 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments, and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.